Slow Capital Inc. Sells 24,335 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Slow Capital Inc. cut its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 28.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 61,575 shares of the company's stock after selling 24,335 shares during the period. Slow Capital Inc. owned 0.07% of CRISPR Therapeutics worth $2,424,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. KBC Group NV lifted its holdings in shares of CRISPR Therapeutics by 2,047.4% during the 4th quarter. KBC Group NV now owns 60,514 shares of the company's stock valued at $2,382,000 after acquiring an additional 57,696 shares in the last quarter. PFG Investments LLC grew its position in CRISPR Therapeutics by 9.9% in the 4th quarter. PFG Investments LLC now owns 10,603 shares of the company's stock worth $417,000 after purchasing an additional 952 shares during the last quarter. Hedges Asset Management LLC grew its position in CRISPR Therapeutics by 5.1% in the 4th quarter. Hedges Asset Management LLC now owns 24,350 shares of the company's stock worth $958,000 after purchasing an additional 1,188 shares during the last quarter. MCF Advisors LLC acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $80,000. Finally, Arkadios Wealth Advisors lifted its stake in shares of CRISPR Therapeutics by 7.7% in the 4th quarter. Arkadios Wealth Advisors now owns 12,161 shares of the company's stock worth $479,000 after acquiring an additional 866 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Needham & Company LLC reissued a "buy" rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Bank of America dropped their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Barclays decreased their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating for the company in a report on Wednesday, November 6th. JMP Securities reaffirmed a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Friday, December 20th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of "Hold" and an average target price of $78.38.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 15,000 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Trading Down 0.1 %

Shares of NASDAQ CRSP traded down $0.04 during midday trading on Tuesday, reaching $41.81. The company's stock had a trading volume of 1,420,899 shares, compared to its average volume of 2,032,889. CRISPR Therapeutics AG has a fifty-two week low of $36.52 and a fifty-two week high of $91.10. The stock has a market capitalization of $3.57 billion, a price-to-earnings ratio of -14.77 and a beta of 1.68. The stock has a 50 day simple moving average of $44.09 and a 200-day simple moving average of $47.46.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same period last year, the company earned ($1.41) earnings per share. As a group, equities analysts anticipate that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.